hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06386354 id: 2023-464-1 briefTitle: Residual Neuromuscular Block in the Post-Anesthetic Unit and Postoperative Complications acronym: Porcerito overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-06-30 date: 2024-06-30 date: 2024-04-26 date: 2024-04-26 name: Dr. Negrin University Hospital class: OTHER briefSummary: The use of neuromuscular blockers (NMB) is essential to optimize surgical conditions, ensure patient immobility during the intervention and prevent complications derived from involuntary movements. Intraoperative monitoring of neuromuscular relaxation allows the depth of neuromuscular blockade to be accurately evaluated, guaranteeing ideal conditions for the surgical team. Residual neuromuscular blockade (RNMB) is the persistence of muscle paralysis after the administration of NMB during a surgical intervention. The appearance of RNMB poses substantial challenges in the postoperative period, as it has negative repercussions for the safety and well-being of the patient. conditions: Postoperative Neuromuscular Block conditions: Postoperative Complications studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Train-of-four measure: Residual Neuromuscular Block measure: Residual Neuromuscular Block measure: Postoperative complications sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ángel Becerra city: Las Palmas De Gran Canaria state: Las Palmas zip: 35019 country: Spain lat: 28.09973 lon: -15.41343 hasResults: False
nctId: NCT06386341 id: W23.154 briefTitle: QoL in OSA patiënts Treated With MMA Surgery. acronym: QOMAS overallStatus: RECRUITING date: 2023-08-02 date: 2026-08-02 date: 2026-08-02 date: 2024-04-26 date: 2024-04-26 name: Diakonessenhuis, Utrecht class: OTHER briefSummary: The aim of this observational study is to evaluate the impact of maxillomandibular advancement surgery on the quality of life in patients treated with obstructive sleep apnea.
Patients will answer online surverys about their QoL and there will be data collected like length, weight and blood pressure. conditions: Sleep Apnea, Obstructive conditions: Quality of Life studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 80 type: ESTIMATED name: Maxillomandibular Advancement Surgery measure: SF-36 measure: OHIP-14 measure: ESS measure: FOSQ measure: EQ-5D-3L measure: OQLQ sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Diakonessenhuis status: RECRUITING city: Utrecht zip: 3582KE country: Netherlands name: Susanne Leij role: CONTACT phone: 088-250 6172 email: sleij@diakhuis.nl name: Maurits de Ruiter, MD, DDS, PHD role: PRINCIPAL_INVESTIGATOR name: Haya Al-Bayyati role: SUB_INVESTIGATOR lat: 52.09083 lon: 5.12222 hasResults: False
nctId: NCT06386328 id: A129_03FDI2317 briefTitle: A Clinical Trial to Evaluate the Food Effect of CKD-378 overallStatus: NOT_YET_RECRUITING date: 2024-05-03 date: 2024-06-03 date: 2024-06-11 date: 2024-04-26 date: 2024-04-26 name: Chong Kun Dang Pharmaceutical class: INDUSTRY briefSummary: A clinical trial to evaluate the food effect of CKD-378 conditions: Type II Diabetes Mellitus studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: CKD-378, QD, PO measure: AUCt of CKD-378 measure: Cmax of CKD-378 sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06386315 id: MC230808 id: NCI-2024-03242 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: 23-010273 type: OTHER domain: Mayo Clinic Institutional Review Board id: MC230808 type: OTHER domain: Mayo Clinic briefTitle: Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-05-30 date: 2024-05-30 date: 2024-04-26 date: 2024-04-29 name: Mayo Clinic class: OTHER briefSummary: This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard of care radiation treatment for indolent non-Hodgkin lymphoma is usually delivered in 12 treatments. Studies have shown indolent lymphoma to be sensitive to radiation treatment, however, larger doses have higher rates of toxicities. A reduced radiation dose may be safe, tolerable and/or effective compared to standard of care radiation dose in treating patients with indolent non-Hodgkin lymphoma. conditions: Indolent B-Cell Non-Hodgkin Lymphoma conditions: Recurrent Indolent B-Cell Non-Hodgkin Lymphoma conditions: Refractory Indolent B-Cell Non-Hodgkin Lymphoma conditions: Recurrent Indolent Non-Hodgkin Lymphoma conditions: Refractory Indolent Non-Hodgkin Lymphoma studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 112 type: ESTIMATED name: Computed Tomography name: Endoscopic Procedure name: Involved-site Radiation Therapy (3 Fractions) name: Involved-site Radiation Therapy (12 Fractions) name: Positron Emission Tomography name: Questionnaire Administration measure: Incidence of grade 2 or higher acute adverse events (AEs) measure: Response rate measure: Time to progression rate measure: Patient reported quality of life sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Arizona city: Scottsdale state: Arizona zip: 85259 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: mayocliniccancerstudies@mayo.edu name: William G. Rule, MD role: PRINCIPAL_INVESTIGATOR lat: 33.50921 lon: -111.89903 facility: Mayo Clinic in Florida city: Jacksonville state: Florida zip: 32224-9980 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: mayocliniccancerstudies@mayo.edu name: Bradford S. Hoppe, MD, MPH role: PRINCIPAL_INVESTIGATOR lat: 30.33218 lon: -81.65565 facility: Mayo Clinic in Rochester city: Rochester state: Minnesota zip: 55905 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: mayocliniccancerstudies@mayo.edu name: Scott C. Lester, MD role: PRINCIPAL_INVESTIGATOR lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06386302 id: CSIIT-A36 briefTitle: Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia overallStatus: NOT_YET_RECRUITING date: 2024-05-30 date: 2027-12-30 date: 2027-12-30 date: 2024-04-26 date: 2024-04-26 name: Institute of Hematology & Blood Diseases Hospital, China class: OTHER briefSummary: To evaluate the feasibility, effectiveness and safety of chidamide combined with venetoclax and azacitidine in the treatment of newly diagnosed acute myeloid leukemia (AML) who are not suitable for intensive chemotherapy. conditions: AML conditions: Acute Myeloid Leukemia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 184 type: ESTIMATED name: Chidamide name: Venetoclax name: azacitidine measure: Composite complete remission rate measure: Overall response rate (ORR) measure: Overall survival (OS) measure: MRD response rate sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06386289 id: CNV202202 briefTitle: Safety, Performance of CEREGLIDE 92 Intermediate Catheter in Treatment of Acute Ischemic Stroke acronym: SPLENDID overallStatus: NOT_YET_RECRUITING date: 2024-09-01 date: 2026-02-28 date: 2026-06-30 date: 2024-04-26 date: 2024-04-26 name: Cerenovus, Part of DePuy Synthes Products, Inc. class: INDUSTRY briefSummary: The device is indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease conditions: Acute Ischemic Stroke studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 172 type: ESTIMATED name: Cereglide 92 measure: First pass reperfusion sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Iowa Hospital & Clinics city: Iowa City state: Iowa zip: 52242 country: United States lat: 41.66113 lon: -91.53017 facility: JFK Medical Center city: Edison state: New Jersey zip: 08820 country: United States lat: 40.51872 lon: -74.4121 facility: Westchester Medical Center city: Valhalla state: New York zip: 10595 country: United States lat: 41.07482 lon: -73.77513 facility: Vanderbilt University Medical Center city: Nashville state: Tennessee zip: 37232 country: United States lat: 36.16589 lon: -86.78444 facility: University of Utah city: Salt Lake City state: Utah zip: 84132 country: United States lat: 40.76078 lon: -111.89105 facility: West Virginia University city: Morgantown state: West Virginia zip: 26506 country: United States lat: 39.62953 lon: -79.9559 hasResults: False
nctId: NCT06386276 id: 00025986 briefTitle: Surgical TReatment of Women With Deep ENDometriosis acronym: TrEnd overallStatus: RECRUITING date: 2023-10-11 date: 2028-06-30 date: 2029-06-30 date: 2024-04-26 date: 2024-04-26 name: Casa di Cura Privata 'Malzoni - Villa dei Platani' S.P.A. class: OTHER briefSummary: TrEnd trial is aimed to collect data from consecutive patients undergoing segmental sigmoid colon/rectal resection for deep endometriosis. The main purpose of this project is to gather a large series of cases treated using standardized surgical procedures, allowing a precise evaluation of complications and long-term outcomes. conditions: Deep Endometriosis conditions: Surgery studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: OTHER count: 250 type: ESTIMATED name: Colorectal bowel resection measure: To document the surgical strategies adopted for treating patients with deep endometriosis undergoing to sigmoid colon/rectal resection measure: To assess the rate of complications measure: To assess the rate of conversion to open surgery measure: To assess the rate of endometriosis-free bowel resection margins measure: To assess the rate of recurrence measure: To assess the intraoperative blood loss measure: To assess the operating time measure: To assess the gastrointestinal function recovery measure: To assess the duration of hospital stay measure: To assess the reproductive outcomes sex: FEMALE minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Casa Di Cura Malzoni Villa Platani Spa status: RECRUITING city: Avellino state: Campania zip: 83100 country: Italy name: Francesca Falcone, MD role: CONTACT email: francesca.falcone3@icloud.com name: Mario Malzoni, MD role: PRINCIPAL_INVESTIGATOR name: Francesca Falcone, MD role: PRINCIPAL_INVESTIGATOR lat: 40.91494 lon: 14.79103 hasResults: False
nctId: NCT06386263 id: D9673R00032 briefTitle: HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada acronym: HER-TEMPO overallStatus: NOT_YET_RECRUITING date: 2024-04-26 date: 2025-04-04 date: 2025-04-04 date: 2024-04-26 date: 2024-04-26 name: AstraZeneca class: INDUSTRY name: Daiichi Sankyo briefSummary: Trastuzumab deruxtecan (T-DXd) has been studied in multiple global prospective DESTINY-Breast trials and has a marketing authorization from Health Canada for patients with HER2-positive metastatic breast cancer (mBC) and HER2-low mBC, respectively.
Multiple stakeholders, including clinicians, patients, regulators, and healthcare decision makers, are interested in real-world treatment-related outcomes in order to better represent the effectiveness of therapies in routine care settings. conditions: Unresectable Breast Cancer conditions: Metastatic Breast Cancer conditions: HER2-low Expressing Breast Cancer conditions: HER2-positive Breast Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 75 type: ESTIMATED name: Trastuzumab deruxtecan measure: Early treatment discontinuation rates measure: Dose modifications measure: Real world time to treatment discontinuation (rwTTD) measure: Reasons for treatment discontinuations measure: Median treatment duration and dose intensity sex: ALL minimumAge: 18 Years maximumAge: 130 Years stdAges: ADULT stdAges: OLDER_ADULT facility: NavieGo Patient ProgramsLtd & Affiliate city: Oakville state: Ontario zip: L6H 1A7 country: Canada lat: 43.45011 lon: -79.68292 hasResults: False
nctId: NCT06386250 id: 0005 briefTitle: Comparison of Regional Block, Caudal Block and Wound Infiltration in Inguinal Hernitomy acronym: Painseverity overallStatus: COMPLETED date: 2019-01-05 date: 2020-01-06 date: 2020-01-06 date: 2024-04-26 date: 2024-04-26 name: King Edward Medical University class: OTHER briefSummary: Background: Although Inguinal herniotomy in children is taken as a day care procedure, post-operative pain management still remain controversial in these cases and superiority of wound infiltration, caudal block or regional block over each isn't known.
Objective: The objective of the study was compare regional block, caudal block and wound infiltration for post-operative pain management in children undergoing inguinal herniotomy conditions: Postoperative Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Regional block group (Group A), wound infiltration group (Group B), caudal block group (Group C) primaryPurpose: PREVENTION masking: NONE count: 300 type: ACTUAL name: regional block name: Caudal block name: Epidural measure: Postoperative pain intensity measure: postoperative pain intesity sex: ALL minimumAge: 3 Years maximumAge: 12 Years stdAges: CHILD facility: Muhammad Sharif city: Lahore state: Punjab zip: 53711 country: Pakistan lat: 31.558 lon: 74.35071 hasResults: False
nctId: NCT06386237 id: UVienna_NDNL_1 briefTitle: Nutritional Modulation of Cognition and Brain Activity overallStatus: RECRUITING date: 2024-04-08 date: 2025-02-28 date: 2025-02-28 date: 2024-04-26 date: 2024-04-26 name: University of Vienna class: OTHER name: Medical University of Vienna briefSummary: The aim of the present study is to investigate the effects of different meal interventions on cognition (i.e., learning and decision making) and brain activity in healthy participants. conditions: Nutrition, Healthy conditions: Cognitive Change conditions: Brain Activity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: BASIC_SCIENCE masking: NONE count: 40 type: ESTIMATED name: Dietary intervention: Standardized breakfast with varying amounts of macronutrients (in particular carbohydrate/protein ratios) measure: Changes in cognition/behavior I measure: Changes in cognition/behavior II measure: Changes in brain activity measure: Changes in metabolic parameters I measure: Changes in metabolic parameters II measure: Changes in metabolic parameters III measure: Changes in metabolic parameters IV measure: Changes in subjective affective state measure: Changes in experienced hunger sex: ALL minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: University of Vienna status: RECRUITING city: Vienna zip: 1090 country: Austria name: Stefan Schulreich, Prof. Dr. role: CONTACT phone: +4314277 phoneExt: 54960 email: stefan.schulreich@univie.ac.at lat: 48.20849 lon: 16.37208 hasResults: False
nctId: NCT06386224 id: 1R01DK137520-01 type: NIH link: https://reporter.nih.gov/quickSearch/1R01DK137520-01 briefTitle: Internet-Delivered Pain Self-Management for Persons With Acute Recurrent and Chronic Pancreatitis Pain acronym: IMPACT-2 overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-03-31 date: 2026-09-30 date: 2024-04-26 date: 2024-04-26 name: Seattle Children's Hospital class: OTHER name: University of Kentucky briefSummary: Severe and disabling abdominal pain is common in individuals with chronic pancreatitis. Although pain is associated with reduced quality of life and high economic and societal costs, there are limited effective options for pain management in this population. This study proposes an evidence-based psychological intervention approach using an internet-delivered pain self-management program to minimize the impact of pain and improve quality of life. The ultimate goal is to maximize the public health impact of the intervention with successful implementation and dissemination to pancreas clinics and to the community. conditions: Pancreatitis conditions: Chronic Pancreatitis conditions: Acute Recurrent Pancreatitis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants randomized to the active intervention arm will receive access to the Pancreatitis Pain Course to learn cognitive-behavioral (CBT) pain self-management skills (e.g., changing negative thoughts, relaxation, activity pacing, goal setting). Participants randomized to the control arm will receive access to an education website. primaryPurpose: SUPPORTIVE_CARE masking: TRIPLE maskingDescription: Participants are not informed of their condition assignment and both receive online programs for chronic pancreatitis. Investigators are blinded \& masked to study condition, and all outcomes are assessed via self-reported REDCap surveys. Care providers are not involved in the study (N/A). whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 280 type: ESTIMATED name: Internet-delivered pain self-management (CBT Condition) name: Education Program measure: Change in pain severity and pain interference measure: Change in disease-specific pain measure: Change in physical functioning measure: Change in psychological functioning measure: Change in pain catastrophizing measure: Change in sleep disturbance measure: Change in disease specific health-related quality of life measure: Change in patient global impression of change measure: Change in opioid use measure: Treatment acceptability measure: Change in substance use sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Seattle Children's Hospital city: Seattle state: Washington zip: 98105 country: United States name: Tonya Palermo, PhD role: CONTACT phone: 206-884-4208 email: tonya.palermo@seattlechildrens.org name: Tonya M Palermo, PhD role: PRINCIPAL_INVESTIGATOR lat: 47.60621 lon: -122.33207 hasResults: False
nctId: NCT06386211 id: BDR17228 id: BDR17228 type: OTHER domain: Sanofi Identifier briefTitle: Bioavailability Study of Magne-B6 New Formulation overallStatus: NOT_YET_RECRUITING date: 2024-05-06 date: 2024-06-15 date: 2024-06-15 date: 2024-04-26 date: 2024-04-26 name: Opella Healthcare Group SAS, a Sanofi Company class: INDUSTRY briefSummary: The purpose of the study is to assess the relative bioavailability of two Magne-B6 preparations, in fasting conditions. conditions: Healthy Volunteers studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: MAGNE-B6 Oral Solution name: MAGNE-B6 New Formulation Tablet measure: Maximal Observed Concentration (Cmax) of Magnesium in Plasma measure: Area Under the Concentration-time Curve from Time Zero Until time 12 hour (h) (AUC0-12) of Magnesium in Plasma measure: Area Under the Concentration-time Curve from Time Zero Until time 24 h (AUC0-24) of Magnesium in Plasma measure: Maximal Observed Concentration (Cmax) of Pyridoxine in Plasma measure: Area Under the Concentration-time Curve from Time Zero Until the Last Observed Concentration (AUClast) of Pyridoxine in Plasma measure: Area Under the Concentration-time Curve from Time Zero to Infinity (extrapolated) (AUC0-infinity) of Pyridoxine in Plasma measure: Time When the Maximal Concentration is Observed (Tmax) of Magnesium in Plasma measure: Time When the Maximal Concentration is Observed (Tmax) of Pyridoxine in Plasma measure: Cumulative Amount of Unchanged Drug Excreted into the Urine From Time Zero to the Time Point 24 hours (Ae0-24) of Magnesium in Urine measure: Percentage of Participants with Treatment Emergent Adverse Events (TEAEs) sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
nctId: NCT06386198 id: 23-40699 briefTitle: HEalth Advocate for Liver Transplantation: Improving Transition of Care for Adolescent Liver Transplant Recipients acronym: HEAL-Tx:ToC overallStatus: RECRUITING date: 2024-03-03 date: 2026-06-30 date: 2026-06-30 date: 2024-04-26 date: 2024-04-26 name: University of California, San Francisco class: OTHER name: American Society of Transplantation briefSummary: The Health Advocate for Liver Transplant (HEAL-Tx) Transition of Care Pilot is a nonrandomized, open-label intervention pilot of a health advocate intervention aimed to assess feasibility and acceptability of integrating a Health Advocate onto the transplant team to help adolescents transition their care to adult transplant teams. Across studies, health advocate roles vary, and can include coordinating medical care treatment, facilitating financial assistance (e.g., taxi vouchers), and connecting patients to community resources, which can improve self-management, mitigate social risks, and lead to better communication between the healthcare system and the family. In this pilot, the investigators will adapt this intervention for adolescent/young adult liver transplant patients and measure acceptability and feasibility according to RE-AIM. conditions: Liver Transplant; Complications conditions: Pediatric ALL studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 20 type: ESTIMATED name: Health Advocate measure: Changes in patient experience measure: Change in medication adherence using MLVI measure: The quality of health advocate interactions with the participants, healthcare team, and community-based resources. measure: A qualitative assessment of patient and healthcare provider satisfaction with the Health Advocate intervention. sex: ALL minimumAge: 18 Years maximumAge: 25 Years stdAges: ADULT facility: University of California San Francisco status: RECRUITING city: San Francisco state: California zip: 94158 country: United States name: Emily Stekol role: CONTACT phone: 415-502-3190 email: emily.stekol@ucsf.edu name: Sharad Wadhwani, MD, MPH role: PRINCIPAL_INVESTIGATOR lat: 37.77493 lon: -122.41942 facility: Children's Healthcare of Atlanta status: NOT_YET_RECRUITING city: Atlanta state: Georgia zip: 30345 country: United States name: Nitika Gupta role: CONTACT name: Nitika Gupta role: PRINCIPAL_INVESTIGATOR lat: 33.749 lon: -84.38798 hasResults: False
nctId: NCT06386185 id: DRAPE briefTitle: Developing the Probability Algorithm for Pulmonary Hypertension Echocardiography acronym: DRAPE overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2026-07-01 date: 2026-11-01 date: 2024-04-26 date: 2024-04-26 name: Royal United Hospitals Bath NHS Foundation Trust class: OTHER name: Sheffield Teaching Hospitals NHS Foundation Trust name: Royal Free Hospital NHS Foundation Trust name: Golden Jubilee National Hospital name: Papworth Hospital NHS Foundation Trust name: University of Bath briefSummary: The goal of this observational study is to assess the efficacy that the addition of novel markers cardiac function, particularly of right ventricular (RV) function in echocardiography, and ECG have in detecting pulmonary hypertension.